Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
(S)-5-methyloxazolidin-2-one → (S)-3-{5-[4-(3,5-dimethylpyridin-2-yl)piperazine-1-carbonyl]pyridin-2-yl}-5-methyloxazolidin-2-one
참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|---|---|---|
| 반응물 | (S)-5-methyloxazolidin-2-one | HCID 21794663 | — |
| 반응물 | (6-Bromopyridin-3-yl)[4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl]methanone | HCID 58484661 | — |
| 생성물 | (S)-3-{5-[4-(3,5-dimethylpyridin-2-yl)piperazine-1-carbonyl]pyridin-2-yl}-5-methyloxazolidin-2-one | HCID 58484829 | 89.6% |
반응 단계
By reaction and treatment in the same manner as in Example 1 and using (6-bromopyridin-3-yl)[4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl]methanone (748 mg) described in Preparation Example 73 and (S)-5-methyloxazolidin-2-one (243 mg) described in Preparation Example 42, the title compound (706 mg) was obtained.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| 특허 번호 | US08354401B2 |
| 출처 데이터셋 | uspto-grants-2013_01 |
| ORD ID | ord-f6d5ebf0fd394f569629d14b29bbdd63 |
| 출처 메모 | uspto-grants-2013_01 |